Study Stopped
The start of the study was temporarily interrupted due to the COVID-19 pandemic. Subsequently, it was not feasible to initiate the study due to changes in the healthcare system for patient follow-up. For this reason, the study was withdrawn.
Telematic Model Integrated in the Transversal Care of the Secondary Prevention of Patients With Stroke
Effectiveness of a Telematic Model Integrated in the Transversal Care of the Secondary Prevention of Patients With Stroke
1 other identifier
observational
N/A
1 country
1
Brief Summary
In Spain, stroke is the leading cause of death in women and disability in adults, which is why it is currently one of the most important public health problems. It is known that the main cause of stroke is the lack of control of cardiovascular risk factors (CRF). Strategies have been diversified for patients with severe neurological involvement, while those without or with mild involvement, susceptible to repeat a stroke, have a very heterogeneous approach. Objective: Design, implement and evaluate the effectiveness of the transversal telematic model of secondary prevention in patients who have suffered a stroke. Methodology: Randomized clinical trial with a control group, open and multicentre. A total of 70 patients (35 per group) will be included who meet all the inclusion criteria and none of exclusion, attended by an acute stroke in the Hospital Verge de la Cinta de Tortosa. Variables: sociodemographic and clinical, FRC, stage of change, therapeutic compliance and CV. Outcome variables: impact of the stroke using the scale (SIS-16); control of CRF, new vascular events and mortality at 3, 6, 12, 18 and 24 months, integrable in the practice and computerized clinical history (HCI). Interventions: control and education for the patient's health to promote self-care and empowerment, and enhance pharmacological compliance. The telematic model has been developed through clinical practice guides of primary care and the most recent publications on the subject referenced. Export of data directly from the HCI. Analysis of results with the SPSS 23.0 program, using regression and survival models.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Oct 2021
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 5, 2018
CompletedFirst Posted
Study publicly available on registry
November 6, 2018
CompletedStudy Start
First participant enrolled
October 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedFebruary 14, 2024
February 1, 2024
Same day
October 5, 2018
February 12, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Stroke Impact Scale
Change from Baseline The Stroke Impact Scale for disability at 3, 6, 12, 18 and 24 months. Score range \[16-80\].
At the beginning of the enrollment, 3, 6 ,12, 18 and 24 months later.
Study Arms (2)
Stroke patients
Control group included people with ischemic or haemorragic stroke in Terres de l'Ebre, Spain.
Telematic model treatment of patients with Stroke
The intervention group included control and education for the patient's health to promote self-care and empowerment, and enhance pharmacological compliance. The telematic model has been developed through clinical practice guides of primary care and the most recent publications on the subject referenced.
Interventions
Intervention group (n=35) Control group (n=35)
Eligibility Criteria
Calculated for two independent samples, variable SIS stroke impact scale result (DS 1.6). Accepting an alpha risk of 0.05 and a beta risk of less than 0.2 in a bilateral contrast, 35 subjects are needed in the first group and 35 in the second to detect a difference equal to or greater than 0.18 units. It is assumed that the common standard deviation is 0.25. A tracking loss rate has been estimated of 10%.
You may qualify if:
- Male and female patients ≥18 years old, diagnosed of established ischemic stroke and / or TIA and attended by the HTVC neurology service, on discharge from home and with habitual residence in the Ebro Lands to be able to follow up .
- Informed consent of the signed study.
You may not qualify if:
- Patients suffering from other neurological injuries that interfere with the follow-up (established strokes, with or without MCA deviation, glioblastomas, etc.), life expectancy \<6 months, modified Rankin scale score (MRS) ≥3 and present language barrier and / or aphasia.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Silvia Reverté
Tortosa, Tarragona, 43500, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 5, 2018
First Posted
November 6, 2018
Study Start
October 1, 2021
Primary Completion
October 1, 2021
Study Completion
December 31, 2023
Last Updated
February 14, 2024
Record last verified: 2024-02
Data Sharing
- IPD Sharing
- Will not share